Tata India Pharma & HealthCare Fund
The scheme seeks long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Growthvine rating: 3/5 — ranked #30 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹32.16 (as of 2026-10-01) |
|---|
| AUM | ₹1,565 Cr |
|---|
| Expense ratio | 1.80% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Rajat Srivastava |
|---|
| Exit load | 0.25% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 12.34% |
|---|
| Sharpe ratio | 0.83 |
|---|
| Standard deviation | 16.35% |
|---|
| Max drawdown | −21.94% |
|---|
| Alpha | -2.81 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 93.6% of NIFTY Pharma's upside and 93.4% of its downside.
Market cap allocation
| Large cap | 23.4% |
|---|
| Mid cap | 36.3% |
|---|
| Small cap | 40.3% |
|---|
Concentration
| Top 5 holdings | 30.3% |
|---|
| Top 10 holdings | 50.2% |
|---|
| Total holdings | 41 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.4%
- HealthCare Global Enterprises Limited — 6.3%
- Divis Laboratories Ltd. — 5.7%
- Abbott India Ltd. — 5.4%
- Rainbow Childrens Medicare Limited — 4.5%
- Apollo Hospitals Enterprises Ltd. — 4.3%
- Cipla Ltd. — 4.3%
- Dr. Reddys Laboratories Ltd. — 4.2%
- Max Healthcare Institute Limited — 3.8%
- Fortis Healthcare Ltd — 3.3%
Top sectors
- Pharma & Biotech — 58.3%
- Healthcare — 34.1%
- Fertilisers — 5.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 6.5% | Q2 | #23 of 76 |
| 2025 | −4.9% | Q4 (Bottom) | #56 of 69 |
| 2024 | 40.4% | Q1 (Top) | #9 of 58 |
| 2023 | 36.6% | Q3 | #25 of 48 |
| 2022 | −8.0% | Q3 | #35 of 46 |